75N95020Q00033

Submitted by tjugumha on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Acquisition of PathHunter CHO-K1 GPR151 β-Arrestin Orphan GPCR Cell Line, or brand equal, to perform high-throughput screening
Contracting Office
National Center for Advancing Translational Sciences (NCATS)

Contact Points

Primary Contract Specialist

Mark
McNally
mark.mcnally@nih.gov

Secondary Contracting Officer

Hunter
Tjugum
hunter.tjugum@nih.gov
NAICS Code Number
541713
Research and Development in Nanotechnology
Small Business Size Standard
1,000 employees
FPDS Classification Code
6505 Drugs and Biologicals
Delivery of Goods
Within 30 days after receipt of order (ARO)
Set-Aside Status
Full Set Aside
Set-Aside Type
Small Business (SB)
Competition Status
Brand Name or Equal
Brand Name
Eurofins Discoverx Corporation's PathHunter CHO-K1 GPR151 β-Arrestin Orphan GPCR Cell Line, Item No. 93-0381C2A, Quantity: 1
Rationale/ Salient Characteristics
The brand equal item must meet the following salient physical, functional, or performance characteristics of the brand-name item to be acceptable for award: • Accession Number: NM_194251 (GPR151); • Stability express GPR151 protein; • Cell model system that can be used to evaluate GPR151 activation and function; • Engineered to co-express the PK tagged GPR151 and the Enzyme Acceptor (EA) tagged β-Arrestin; • Activation of the GPR151-PK induces β-Arrestin-EA recruitment, forcing complementation of the two β-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal; • Free of mycoplasma contamination; • Confirmed to be stable through 10 passages with no significant change in GPCR-PK expression level; and • Cell Type: CHO-K1.
Background/Description of Requirement

This notice of proposed contract action is posted in accordance with FAR 5.101(a)(2). A copy of the solicitation may be obtained from the contact points.

The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.

As a part of HEAL (Helping to End Addiction Long-term) Initiative launched by NIH this year, NCATS is currently pursuing screening of several opioid-related targets for primary and follow-up approaches. GPCR cell lines described here provide a novel and HTS-amenable handle to measure the activity of these important targets. To this end, NCGC is in need of the following brand-name or equal cell lines to enable these novel drug discovery efforts:

Item No.: 93-0381C2A
Manufacturer: Eurofins Discoverx Corporation
Item Description: PathHunter CHO-K1 GPR151 β-Arrestin Orphan GPCR Cell Line, or brand equal
Quantity: One (1)
Unit of Issue: Each

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.